MCID: BRS099
MIFTS: 63

Breast Ductal Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Breast Ductal Carcinoma

MalaCards integrated aliases for Breast Ductal Carcinoma:

Name: Breast Ductal Carcinoma 12 15
Ductal Breast Carcinoma 55 6 72
Mammary Ductal Carcinoma 72
Carcinoma, Ductal 44
Ductal Carcinoma 72
Duct Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3007
MeSH 44 D044584
SNOMED-CT 68 82711006
UMLS 72 C0021367 C1176475 C1527349

Summaries for Breast Ductal Carcinoma

Disease Ontology : 12 A breast carcinoma that derives from the lining of milk ducts.

MalaCards based summary : Breast Ductal Carcinoma, also known as ductal breast carcinoma, is related to bile duct cancer and breast cystic hypersecretory carcinoma. An important gene associated with Breast Ductal Carcinoma is RAD54L (RAD54 Like), and among its related pathways/superpathways are ERK Signaling and Nanog in Mammalian ESC Pluripotency. The drugs Vinorelbine and Pertuzumab have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and testes, and related phenotypes are Decreased viability in esophageal squamous lineage and Decreased cell migration

Related Diseases for Breast Ductal Carcinoma

Diseases related to Breast Ductal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 429, show less)
# Related Disease Score Top Affiliating Genes
1 bile duct cancer 33.4 TP53 MET EGFR CCND1
2 breast cystic hypersecretory carcinoma 33.3 ERBB2 CDH1
3 intrahepatic cholangiocarcinoma 33.3 TP53 EGFR CTNNB1 CDH1
4 cholangiocarcinoma 31.4 TP53 TFF1 MET KRT8 ERBB2 EGFR
5 papillary adenocarcinoma 31.2 TP53 PGR ERBB2 CDH1
6 tubular adenocarcinoma 31.1 PGR ESR1 ERBB2 CDH1
7 pleomorphic adenoma 31.0 TP53 ERBB2 AR
8 cystadenocarcinoma 31.0 TP53 PGR ERBB2
9 in situ carcinoma 31.0 TP53 PGR ESR1 ERBB2 EGFR CDH1
10 pleomorphic adenoma carcinoma 30.9 TP53 ERBB2
11 adenocarcinoma 30.8 TP53 ERBB2 EGFR CTNNB1 CDH1 CCND1
12 comedo carcinoma 30.7 ESR1 ERBB2
13 renal cell carcinoma, papillary, 1 30.7 TP53 MET ERBB2
14 papillary carcinoma 30.7 PGR MET ERBB2 CDH1
15 transitional cell carcinoma 30.7 TP53 KRT8 ERBB2 EGFR CDH1
16 carcinosarcoma 30.6 TP53 PGR ERBB2 CTNNB1
17 adenoid cystic carcinoma 30.5 TP53 PGR ERBB2 CTNNB1 CDH1 CCND1
18 sporadic breast cancer 30.4 TP53 PGR ESR1 ERBB2 BRCA1
19 gallbladder cancer 30.3 TP53 NME1 ERBB2 EGFR CDH1
20 oral cancer 30.2 TP53 EGFR CDH1 CCND1
21 differentiated thyroid carcinoma 30.1 TP53 MET EGFR
22 breast adenocarcinoma 30.0 TP53 ESR1 ERBB2 EGFR CTSD
23 bladder urothelial carcinoma 30.0 TP53 ERBB2 CTNNB1 CDH1 CCND1
24 apocrine adenocarcinoma 29.9 PGR ESR1 ERBB2 AR
25 bladder cancer 29.9 ZFAS1 TP53 ERBB2 EGFR CDH1 CCND1
26 mammary paget's disease 29.8 PGR KRT8 ESR1 ERBB2 EGFR
27 breast fibroadenoma 29.8 PGR NME1 KRT8 ESR1 ERBB2
28 estrogen-receptor positive breast cancer 29.8 TP53 PGR ESR1 ERBB2 EGFR CCND1
29 nasopharyngeal carcinoma 29.8 TP53 NME1 EGFR CDH1 CCND1
30 lobular neoplasia 29.7 ESR1 ERBB2 CTNNB1 CDH1 BRCA1
31 adenosquamous carcinoma 29.7 TP53 KRT8 EGFR AR
32 sweat gland cancer 29.7 TP53 PGR KRT8 ESR1 ERBB2
33 renal cell carcinoma, nonpapillary 29.7 MET KRT8 EGFR CDH1
34 gastrointestinal system disease 29.6 TP53 ERBB2 EGFR CTNNB1 CDH1 CCND1
35 esophageal cancer 29.5 TP53 ERBB2 EGFR CTNNB1 CDH1 CCND1
36 pancreatic cancer 29.4 TP53 MET ERBB2 EGFR CTNNB1 CDH1
37 squamous cell carcinoma 29.4 TP53 NME1 ERBB2 EGFR CTNNB1 CDH1
38 prostatic hypertrophy 29.4 PGR ESR1 EGFR AR
39 hepatocellular carcinoma 29.3 ZFAS1 TP53 MET EGFR CTNNB1 CDH1
40 gastrointestinal system cancer 29.3 TP53 MET ERBB2 EGFR CTNNB1 CDH1
41 ductal carcinoma in situ 29.3 TP53 PGR KRT8 ESR1 ERBB2 EGFR
42 breast carcinoma in situ 29.2 TP53 PGR MET ESR1 ERBB2 EGFR
43 female breast cancer 29.1 TP53 PGR ESR1 ERBB2 BRCA1 AR
44 breast disease 28.7 TP53 TFF1 PGR ESR1 ERBB2 CTSD
45 gastric cancer 27.7 ZFAS1 TP53 TFF1 NME1 MET ERBB2
46 colorectal cancer 27.4 ZFAS1 TP53 NME1 MET ERBB2 EGFR
47 endometrial cancer 27.2 TP53 PGR ESR1 ERBB2 EGFR CTSD
48 prostate cancer 26.2 ZFAS1 TP53 MET KRT8 ESR1 ERBB2
49 breast cancer 25.6 ZFAS1 TP53 TFF1 RAD54L PIP PGR
50 collecting duct carcinoma 12.7
51 adenosquamous bile duct carcinoma 12.4
52 bile duct carcinoma in situ 12.3
53 squamous cell bile duct carcinoma 12.2
54 nipple duct carcinoma 12.2
55 distal biliary tract carcinoma 11.5
56 klatskin's tumor 11.5
57 extrahepatic bile duct adenocarcinoma 11.5
58 bile duct adenocarcinoma 11.5
59 extrahepatic bile duct small cell adenocarcinoma 11.2
60 renal cell carcinoma, xp11-associated 11.1
61 bile duct cystadenocarcinoma 10.9
62 endometrium carcinoma in situ 10.7 TP53 PGR
63 breast papillomatosis 10.7 ERBB2 CCND1
64 gastric papillary adenocarcinoma 10.7 TP53 ERBB2
65 breast apocrine carcinoma 10.7 PGR ERBB2
66 adult hepatocellular carcinoma 10.7 TP53 CTNNB1
67 scirrhous adenocarcinoma 10.7 PGR ERBB2
68 bartholin's gland adenoma 10.7 PGR ESR1
69 breast intraductal proliferative lesion 10.7 ERBB2 EGFR
70 vestibular gland benign neoplasm 10.7 PGR ESR1
71 brain ependymoma 10.7 TP53 EGFR
72 lung leiomyoma 10.7 PGR ESR1
73 non-proliferative fibrocystic change of the breast 10.7 TP53 ERBB2 CCND1
74 vulvar syringoma 10.7 PGR ESR1
75 tonsil cancer 10.7 TP53 ERBB2 CDH1
76 cerebral convexity meningioma 10.7 TP53 CDH1
77 endometrial clear cell adenocarcinoma 10.6 ESR1 CTSD
78 tongue disease 10.6 TP53 CTNNB1 CDH1
79 vulvar leiomyoma 10.6 PGR ESR1
80 trigonitis 10.6 PGR ESR1
81 breast osteosarcoma 10.6 KRT8 ERBB2
82 vulvar benign neoplasm 10.6 PGR ESR1
83 uterine body mixed cancer 10.6 TP53 PGR ERBB2
84 intracystic papillary adenoma 10.6 PGR ERBB2
85 glassy cell carcinoma of the cervix 10.6 PGR ESR1 ERBB2
86 breast squamous cell carcinoma 10.6 TP53 ERBB2 EGFR
87 cervical carcinosarcoma 10.6 TP53 PGR ESR1
88 intestinal benign neoplasm 10.6 TP53 CTNNB1 CCND1
89 adenosarcoma 10.6 TP53 PGR ESR1
90 progesterone-receptor positive breast cancer 10.6 PGR ESR1 ERBB2
91 mixed cell type cancer 10.6 TP53 PGR ERBB2
92 atypical teratoid rhabdoid tumor 10.6 TP53 CTNNB1 CCND1
93 breast metaplastic carcinoma 10.5 PGR ERBB2
94 esophageal basaloid squamous cell carcinoma 10.5 TP53 EGFR CTNNB1
95 predominantly cortical thymoma 10.5 PGR ESR1
96 penile cancer 10.5 TP53 EGFR CCND1
97 calcifying epithelial odontogenic tumor 10.5 TP53 KRT8
98 serous cystadenocarcinoma 10.5 TP53 PGR ERBB2
99 bladder disease 10.5 TP53 ERBB2 CDH1 CCND1
100 adenomyosis 10.5 PGR ESR1 CDH1
101 chordoma 10.5 MET EGFR CDH1
102 nasopharyngeal disease 10.5 TP53 CTNNB1 CDH1 CCND1
103 tuberculous salpingitis 10.5 ERBB2 BRCA1
104 ovarian serous cystadenocarcinoma 10.5 TP53 PGR ERBB2
105 progesterone-receptor negative breast cancer 10.5 PGR ERBB2 EGFR
106 cervix disease 10.5 TP53 CTNNB1 CDH1 CCND1
107 uterine corpus serous adenocarcinoma 10.5 TP53 ERBB2 BRCA1
108 tongue cancer 10.5 TP53 CTNNB1 CDH1 CCND1
109 adenoma 10.5
110 rare tumor 10.5
111 familial adenomatous polyposis 10.4 TP53 CTNNB1 CDH1 CCND1
112 cancerophobia 10.4 PGR BRCA1
113 oropharynx cancer 10.4 TP53 EGFR CDH1 CCND1
114 cholangitis 10.4
115 mutagen sensitivity 10.4 TP53 CCND1 BRCA1
116 nosophobia 10.4 PGR BRCA1
117 cervical adenocarcinoma 10.4 TP53 PGR ESR1 ERBB2
118 oral cavity cancer 10.4 TP53 ERBB2 EGFR CDH1
119 female reproductive endometrioid cancer 10.4 TP53 PGR ESR1 CTNNB1
120 meningioma, familial 10.4 TP53 PGR ESR1 CDH1
121 pleomorphic carcinoma 10.4 TP53 KRT8 EGFR
122 colorectal adenocarcinoma 10.4 TP53 EGFR CTNNB1 CDH1
123 obstructive jaundice 10.4
124 esophageal disease 10.4 TP53 ERBB2 EGFR CCND1
125 papillary serous adenocarcinoma 10.4 TP53 PGR BRCA1
126 basaloid squamous cell carcinoma 10.4 TP53 KRT8 EGFR
127 nervous system cancer 10.4 TP53 EGFR CCND1
128 tongue squamous cell carcinoma 10.4 TP53 CTNNB1 CDH1
129 cervical clear cell adenocarcinoma 10.4 PGR KRT8 ESR1
130 breast secretory carcinoma 10.4 PGR KRT8 ERBB2
131 bartholin's gland benign neoplasm 10.4 PGR ESR1
132 endometrial stromal sarcoma 10.4 TP53 PGR ESR1 CCND1
133 recurrent respiratory papillomatosis 10.4 TP53 EGFR
134 cervical squamous cell carcinoma 10.3 TP53 KRT8 CTNNB1 CDH1
135 ovarian cancer 1 10.3 TP53 ERBB2 CDH1 BRCA1
136 bilateral breast cancer 10.3 PGR ERBB2 BRCA1
137 breast scirrhous carcinoma 10.3 PGR ESR1 ERBB2 EGFR
138 breast malignant phyllodes tumor 10.3 TP53 PGR
139 luminal breast carcinoma 10.3 PGR ESR1 ERBB2 EGFR
140 spinal chordoma 10.3 MET KRT8 EGFR
141 respiratory system disease 10.3 TP53 EGFR CDH1
142 barrett esophagus 10.3 TP53 TFF1 ERBB2 CCND1
143 infiltrative basal cell carcinoma 10.3 FAP CDH1 AR
144 sclerosing cholangitis 10.3
145 sarcoma, synovial 10.3 MET KRT8 CTNNB1 CDH1
146 glycogen-rich clear cell breast carcinoma 10.2 TP53 PGR ESR1 BRCA1
147 pharynx cancer 10.2 TP53 EGFR CTNNB1 CDH1 CCND1
148 intestinal disease 10.2 TP53 EGFR CTNNB1 CDH1 CCND1
149 breast medullary carcinoma 10.2 PGR ESR1 ERBB2 BRCA1
150 cholangitis, primary sclerosing 10.2
151 kidney cancer 10.2
152 salivary gland carcinoma 10.2
153 facial paralysis 10.2
154 mucoepidermoid carcinoma 10.2
155 li-fraumeni syndrome 10.2 TP53 EGFR BRCA1
156 malignant syringoma 10.2
157 breast neuroendocrine neoplasm 10.2 PIP ERBB2
158 male reproductive system disease 10.2 TP53 CDH1 CCND1 AR
159 inflammatory breast carcinoma 10.2 PGR ESR1 ERBB2 EGFR CDH1
160 diffuse peritoneal leiomyomatosis 10.2 PGR ESR1 AR
161 gender identity disorder 10.2 PGR ESR1 AR
162 peritoneal benign neoplasm 10.2 PGR ESR1 AR
163 leiomyosarcoma 10.2
164 ovarian disease 10.2 TP53 PGR ESR1 BRCA1
165 glioblastoma multiforme 10.1 TP53 MET ERBB2 EGFR CCND1
166 glioblastoma 10.1 TP53 MET ERBB2 EGFR CCND1
167 acinar cell carcinoma 10.1
168 ulcerative colitis 10.1
169 colitis 10.1
170 47,xyy 10.1
171 gynecomastia 10.1 PGR ESR1 AR
172 chromophil renal cell carcinoma 10.1
173 suppression of tumorigenicity 12 10.1 TP53 CTNNB1 CDH1 AR
174 large intestine adenocarcinoma 10.1 PIP CTNNB1 CDH1
175 mastitis 10.1
176 uterine corpus cancer 10.1 TP53 PGR ESR1 ERBB2 BRCA1
177 fallopian tube carcinoma 10.1 TP53 PGR ESR1 ERBB2 BRCA1
178 medulloblastoma 10.1 TP53 ERBB2 EGFR CTNNB1 CCND1
179 synchronous bilateral breast carcinoma 10.1 TP53 PGR ESR1 CCND1 BRCA1
180 bile duct cysts 10.0
181 cholestasis 10.0
182 cholecystitis 10.0
183 giant cell tumor 10.0
184 spindle cell carcinoma 10.0
185 myoepithelial carcinoma 10.0
186 epithelial-myoepithelial carcinoma 10.0
187 laryngeal disease 10.0 TP53 NME1 EGFR CDH1 CCND1
188 breast adenoid cystic carcinoma 10.0 PGR ESR1 ERBB2 AR
189 laryngeal squamous cell carcinoma 10.0 TP53 NME1 EGFR CDH1 CCND1
190 gastric signet ring cell adenocarcinoma 10.0 PIP PGR CDH1
191 retinoblastoma 10.0
192 oncocytoma 10.0
193 pontine tegmental cap dysplasia 10.0
194 choledocholithiasis 10.0
195 neutropenia 10.0
196 familial retinoblastoma 10.0
197 kidney disease 10.0
198 eyelid carcinoma 10.0
199 posttransplant acute limbic encephalitis 10.0
200 lynch syndrome 10.0 TP53 EGFR CTNNB1 CCND1 BRCA1
201 uterine carcinosarcoma 10.0 TP53 PGR ERBB2 EGFR CTNNB1 CDH1
202 primary peritoneal carcinoma 10.0 TP53 PGR ERBB2 EGFR BRCA1
203 cholelithiasis 9.9
204 squamous cell papilloma 9.9
205 syringoma 9.9
206 papilloma 9.9
207 cystadenoma 9.9
208 mucinous adenocarcinoma 9.9
209 pancreatic ductal carcinoma 9.9
210 appendix adenocarcinoma 9.9
211 severe combined immunodeficiency 9.9
212 end stage renal failure 9.9
213 peritonitis 9.9
214 pulmonary embolism 9.9
215 back pain 9.9
216 male reproductive organ cancer 9.9 TP53 CTNNB1 CDH1 CCND1 AR
217 erythroleukemia, familial 9.9
218 pneumothorax, primary spontaneous 9.9
219 digeorge syndrome 9.9
220 thyroid cancer, nonmedullary, 1 9.9
221 lymphoma, hodgkin, classic 9.9
222 neuroblastoma 1 9.9
223 osteogenic sarcoma 9.9
224 tubulin, beta 9.9
225 pituitary adenoma, prolactin-secreting 9.9
226 lymphoma, non-hodgkin, familial 9.9
227 body mass index quantitative trait locus 1 9.9
228 lymphoma 9.9
229 filariasis 9.9
230 pneumothorax 9.9
231 melanoma 9.9
232 plasmacytoma 9.9
233 thyroid gland papillary carcinoma 9.9
234 linitis plastica 9.9
235 hyperglycemia 9.9
236 clear cell renal cell carcinoma 9.9
237 pediatric lymphoma 9.9
238 breast lymphoma 9.9
239 hypoxia 9.9
240 pituitary tumors 9.9
241 rapidly involuting congenital hemangioma 9.9
242 inflammatory myopathy with abundant macrophages 9.9
243 acute liver failure 9.9
244 thyroid carcinoma 9.9
245 ovary epithelial cancer 9.9 TP53 PGR ESR1 ERBB2 CDH1 BRCA1
246 malignant ovarian surface epithelial-stromal neoplasm 9.9 TP53 PGR ESR1 ERBB2 CDH1 BRCA1
247 uterine anomalies 9.9 TP53 PGR ESR1 ERBB2 CTNNB1 CDH1
248 larynx cancer 9.9 TP53 NME1 EGFR CTSD CCND1
249 hereditary leiomyomatosis and renal cell cancer 9.8
250 sarcoidosis 1 9.8
251 varicose veins 9.8
252 chondrosarcoma 9.8
253 gallbladder disease 1 9.8
254 thrombosis 9.8
255 sialadenitis 9.8
256 portal hypertension 9.8
257 hydronephrosis 9.8
258 cholecystolithiasis 9.8
259 pyelonephritis 9.8
260 portal vein thrombosis 9.8
261 pericholangitis 9.8
262 benign breast phyllodes tumor 9.8
263 duodenal ulcer 9.8
264 neuroma 9.8
265 bilirubin metabolic disorder 9.8
266 cystic kidney disease 9.8
267 pancreatic ductal adenocarcinoma 9.8
268 chromophobe renal cell carcinoma 9.8
269 sarcomatoid renal cell carcinoma 9.8
270 leiomyomatosis 9.8
271 keratinizing squamous cell carcinoma 9.8
272 intravenous leiomyomatosis 9.8
273 paraplegia 9.8
274 ileus 9.8
275 hard palate cancer 9.8
276 chronic cholangitis 9.8
277 polymorphous low-grade adenocarcinoma 9.8
278 cervical cancer 9.8 TP53 NME1 ERBB2 CTNNB1 CDH1 CCND1
279 respiratory system cancer 9.8 TP53 MET ERBB2 EGFR CTNNB1 CDH1
280 squamous cell carcinoma, head and neck 9.8 TP53 MET ERBB2 EGFR CTNNB1 CDH1
281 endometrial squamous cell carcinoma 9.8 PGR MET ESR1 CCND1 AR
282 glioma 9.8 ZFAS1 TP53 MET FAP ERBB2 EGFR
283 exanthem 9.8
284 verrucous carcinoma 9.8
285 colonic disease 9.7 TP53 ESR1 EGFR CTSD CTNNB1 CDH1
286 gonadal disease 9.7 TP53 ESR1 ERBB2 BRCA1 AR
287 bartholin's duct cyst 9.7 TP53 PIP AR
288 autoimmune disease 9.7
289 fibrosis of extraocular muscles, congenital, 1 9.7
290 leiomyoma, uterine 9.7
291 lipomatosis, multiple 9.7
292 systemic lupus erythematosus 9.7
293 nephrolithiasis, calcium oxalate 9.7
294 pancreatitis, hereditary 9.7
295 spondyloepiphyseal dysplasia congenita 9.7
296 renal hypodysplasia/aplasia 1 9.7
297 duodenal atresia 9.7
298 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.7
299 laurence-moon syndrome 9.7
300 donohue syndrome 9.7
301 thrombocytopenia 3 9.7
302 wilms tumor 5 9.7
303 alpha-1-antitrypsin deficiency 9.7
304 pulmonary hypertension 9.7
305 bacterial sepsis 9.7
306 paraganglioma 9.7
307 inflammatory myofibroblastic tumor 9.7
308 gastrointestinal carcinoma 9.7
309 ptosis 9.7
310 bone disease 9.7
311 mucositis 9.7
312 polycystic kidney disease 9.7
313 pleomorphic lipoma 9.7
314 sarcoma 9.7
315 respiratory failure 9.7
316 cardiac tamponade 9.7
317 vaginal cancer 9.7
318 goiter 9.7
319 leiomyoma 9.7
320 telangiectasis 9.7
321 rectal disease 9.7
322 sialolithiasis 9.7
323 diarrhea 9.7
324 typhoid fever 9.7
325 extrahepatic cholestasis 9.7
326 clonorchiasis 9.7
327 opisthorchiasis 9.7
328 anus cancer 9.7
329 suppurative cholangitis 9.7
330 acute cholangitis 9.7
331 neuroendocrine tumor 9.7
332 neuroendocrine carcinoma 9.7
333 malignant fibroxanthoma 9.7
334 endodermal sinus tumor 9.7
335 hepatitis b 9.7
336 basal cell carcinoma 9.7
337 dermoid cyst 9.7
338 cystic teratoma 9.7
339 tic disorder 9.7
340 hemoglobinopathy 9.7
341 anuria 9.7
342 papillary cystadenocarcinoma 9.7
343 inverted papilloma 9.7
344 angiomyolipoma 9.7
345 mesenchymal cell neoplasm 9.7
346 mucinous cystadenocarcinoma 9.7
347 anal canal adenocarcinoma 9.7
348 bladder adenocarcinoma 9.7
349 ovary adenocarcinoma 9.7
350 pleural empyema 9.7
351 gastritis 9.7
352 pancreatic adenocarcinoma 9.7
353 liver disease 9.7
354 histiocytoma 9.7
355 spindle cell sarcoma 9.7
356 fibrous histiocytoma 9.7
357 cutaneous fibrous histiocytoma 9.7
358 seminoma 9.7
359 mesenchymal chondrosarcoma 9.7
360 renal pelvis adenocarcinoma 9.7
361 fibrolamellar carcinoma 9.7
362 testicular yolk sac tumor 9.7
363 bile duct adenoma 9.7
364 mature teratoma 9.7
365 malignant acrospiroma 9.7
366 lymphoepithelioma-like carcinoma 9.7
367 cribriform carcinoma 9.7
368 peripheral nervous system disease 9.7
369 conjunctivitis 9.7
370 b-cell lymphoma 9.7
371 pancreatic intraductal papillary-mucinous neoplasm 9.7
372 situs inversus 9.7
373 mediastinitis 9.7
374 appendicitis 9.7
375 choline deficiency disease 9.7
376 lung disease 9.7
377 myeloid sarcoma 9.7
378 neuropathy 9.7
379 crohn's disease 9.7
380 lupus erythematosus 9.7
381 urethral diverticulum 9.7
382 exophthalmos 9.7
383 dacryoadenitis 9.7
384 biliary tract disease 9.7
385 xanthogranulomatous cholecystitis 9.7
386 alopecia 9.7
387 dacryocystitis 9.7
388 lymph node disease 9.7
389 hypereosinophilic syndrome 9.7
390 congenital hepatic fibrosis 9.7
391 biliary tract cancer 9.7
392 bk-virus nephropathy 9.7
393 chromosomal triplication 9.7
394 granulocytopenia 9.7
395 left-sided gallbladder 9.7
396 undifferentiated pleomorphic sarcoma 9.7
397 warthin tumor 9.7
398 cryptogenic cirrhosis 9.7
399 headache 9.7
400 multicystic dysplastic kidney 9.7
401 argyria 9.7
402 thrombotic microangiopathy 9.7
403 overgrowth syndrome 9.7
404 rare renal tumor 9.7
405 thyroid tumor 9.7
406 thoracic benign neoplasm 9.7 TP53 PIP PGR ESR1 ERBB2
407 breast benign neoplasm 9.7 TP53 PIP PGR ESR1 ERBB2
408 postmenopausal atrophic vaginitis 9.7 ESR1 AR
409 endometrial adenocarcinoma 9.7 TP53 PGR ESR1 ERBB2 EGFR CTSD
410 paget disease, extramammary 9.6 PIP ERBB2 AR
411 estrogen-receptor negative breast cancer 9.6 PGR ESR1 ERBB2 BRCA1 AR
412 wilms tumor 1 9.6 TP53 PGR ESR1 ERBB2 CTNNB1 AR
413 microglandular adenosis 9.6 TP53 PIP PGR ERBB2 EGFR
414 papillary hidradenoma 9.6 PIP PGR AR
415 stomach disease 9.5 TP53 TFF1 MET ERBB2 EGFR CTNNB1
416 bartholin's gland disease 9.5 TP53 PIP PGR AR
417 hidradenocarcinoma 9.5 TP53 PIP ESR1 ERBB2 EGFR CCND1
418 lipid-rich carcinoma 9.4 PIP PGR ESR1 ERBB2 EGFR CDH1
419 large intestine cancer 9.4 TP53 NME1 MET ERBB2 EGFR CTNNB1
420 lung cancer 9.4 ZFAS1 TP53 NME1 MET ERBB2 EGFR
421 female reproductive system disease 9.2 TP53 PGR ESR1 ERBB2 EGFR CTNNB1
422 oncocytic breast carcinoma 9.2 PIP PGR ESR1 EGFR AR
423 lung cancer susceptibility 3 9.0 TP53 PIP MET ERBB2 EGFR CTNNB1
424 adamantinoma of long bones 9.0 ZFAS1 TP53 PGR ESR1 ERBB2 EGFR
425 endocrine gland cancer 8.9 TP53 ESR1 ERBB2 EGFR CTNNB1 CDH1
426 pre-malignant neoplasm 8.7 TP53 PIP PGR ESR1 ERBB2 EGFR
427 reproductive system disease 8.6 TP53 PGR ESR1 ERBB2 EGFR CTNNB1
428 ovarian cancer 8.5 ZFAS1 TP53 PGR NME1 ESR1 ERBB2
429 gastric adenocarcinoma 8.4 TP53 TFF1 NME1 MET KRT8 ERBB2

Graphical network of the top 20 diseases related to Breast Ductal Carcinoma:



Diseases related to Breast Ductal Carcinoma

Symptoms & Phenotypes for Breast Ductal Carcinoma

GenomeRNAi Phenotypes related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

26 (showing 3, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.65 BRCA1 CCND1 CDH1 CTNNB1 ERBB2 ESR1
2 Decreased cell migration GR00055-A-1 9.55 CDH3 CTNNB1 CTSD EGFR MET
3 Increased cell death HMECs cells GR00103-A-0 9.1 BRCA1 CTNNB1 EGFR PGR PIP TP53

MGI Mouse Phenotypes related to Breast Ductal Carcinoma:

46 (showing 24, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.46 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
2 endocrine/exocrine gland MP:0005379 10.46 AR BRCA1 CCND1 CDH1 CDH3 CTNNB1
3 digestive/alimentary MP:0005381 10.44 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
4 cardiovascular system MP:0005385 10.43 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR
5 homeostasis/metabolism MP:0005376 10.43 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
6 growth/size/body region MP:0005378 10.42 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
7 immune system MP:0005387 10.39 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
8 mortality/aging MP:0010768 10.37 AR BRCA1 CCND1 CDH1 CTNNB1 CTSD
9 hematopoietic system MP:0005397 10.35 AR BRCA1 CCND1 CTNNB1 CTSD EGFR
10 integument MP:0010771 10.35 AR BRCA1 CCND1 CDH1 CDH3 CTNNB1
11 embryo MP:0005380 10.33 AR BRCA1 CDH1 CTNNB1 EGFR ERBB2
12 neoplasm MP:0002006 10.27 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR
13 limbs/digits/tail MP:0005371 10.18 AR BRCA1 CTNNB1 EGFR ERBB2 ESR1
14 nervous system MP:0003631 10.17 AR BRCA1 CCND1 CTNNB1 CTSD EGFR
15 craniofacial MP:0005382 10.15 AR CCND1 CTNNB1 EGFR ERBB2 MET
16 normal MP:0002873 10.15 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR
17 muscle MP:0005369 10.13 AR BRCA1 CTNNB1 EGFR ERBB2 ESR1
18 liver/biliary system MP:0005370 10.11 AR CTNNB1 EGFR ESR1 KRT8 MET
19 no phenotypic analysis MP:0003012 9.95 CDH1 CTNNB1 EGFR ESR1 MET PGR
20 reproductive system MP:0005389 9.93 AR BRCA1 CCND1 CDH1 CTNNB1 EGFR
21 renal/urinary system MP:0005367 9.8 AR BRCA1 CTNNB1 EGFR ESR1 MET
22 pigmentation MP:0001186 9.72 AR BRCA1 CTNNB1 EGFR TP53
23 respiratory system MP:0005388 9.56 BRCA1 CCND1 CTNNB1 EGFR ERBB2 ESR1
24 skeleton MP:0005390 9.28 AR BRCA1 CCND1 CTNNB1 EGFR ERBB2

Drugs & Therapeutics for Breast Ductal Carcinoma

Drugs for Breast Ductal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 290, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
2
Pertuzumab Approved Phase 3 145040-37-5, 380610-27-5 2540
3
Lapatinib Approved, Investigational Phase 2, Phase 3 388082-78-8, 231277-92-2 208908 9941095
4
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
5
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
6
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
7
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
8
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
9
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
10
Metformin Approved Phase 3 657-24-9 4091 14219
11
Sodium citrate Approved, Investigational Phase 3 68-04-2
12
Fulvestrant Approved, Investigational Phase 3 129453-61-8 104741 17756771
13
Tamoxifen Approved Phase 3 10540-29-1 2733526
14
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
15
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
16
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
17
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
18
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
19
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
20
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
21
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
22
Epirubicin Approved Phase 3 56420-45-2 41867
23
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
24
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
25
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
26
Goserelin Approved Phase 2, Phase 3 65807-02-5, 1233494-97-7 47725 5311128
27
Leuprolide Approved, Investigational Phase 2, Phase 3 53714-56-0 3911 657181
28
Daunorubicin Approved Phase 3 20830-81-3 30323
29
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
30
Toremifene Approved, Investigational Phase 3 89778-26-7 3005573
31
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
32
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
33 Atamestane Investigational Phase 3 96301-34-7
34 Peripheral Nervous System Agents Phase 3
35 Anti-Allergic Agents Phase 3
36 Contraceptive Agents, Male Phase 3
37
Medroxyprogesterone Phase 3 520-85-4 10631
38 Hematinics Phase 3
39 Neurotransmitter Agents Phase 3
40 Gastrointestinal Agents Phase 3
41 Autonomic Agents Phase 3
42 Parasympatholytics Phase 3
43 Cholinergic Agents Phase 3
44 Muscarinic Antagonists Phase 3
45 Mandelic Acids Phase 3
46 Renal Agents Phase 3
47 Cholinergic Antagonists Phase 3
48 Anti-Infective Agents, Urinary Phase 3
49 Ferric Compounds Phase 3
50 Antiviral Agents Phase 2, Phase 3
51 Antimetabolites Phase 2, Phase 3
52 Antimetabolites, Antineoplastic Phase 2, Phase 3
53 Antiparasitic Agents Phase 3
54 Anthelmintics Phase 3
55 Hypoglycemic Agents Phase 3
56 Citrate Phase 3
57 Antineoplastic Agents, Immunological Phase 3
58 Immunosuppressive Agents Phase 3
59 Immunologic Factors Phase 3
60 Antibodies Phase 3
61 Immunoglobulins Phase 3
62 Antibodies, Monoclonal Phase 3
63 Chelating Agents Phase 3
64 Anticoagulants Phase 3
65 Antineoplastic Agents, Phytogenic Phase 3
66 triamcinolone acetonide Phase 3
67 Alkylating Agents Phase 3
68 Triamcinolone diacetate Phase 3
69
Liposomal doxorubicin Phase 3 31703
70 Triamcinolone hexacetonide Phase 3
71 Antibiotics, Antitubercular Phase 3
72 Albumin-Bound Paclitaxel Phase 3
73 Tubulin Modulators Phase 3
74 Anti-Bacterial Agents Phase 3
75 Topoisomerase Inhibitors Phase 3
76 Antimitotic Agents Phase 3
77 Antirheumatic Agents Phase 3
78 Antineoplastic Agents, Alkylating Phase 3
79 Protective Agents Phase 3
80 Adjuvants, Immunologic Phase 3
81 Viscosupplements Phase 3
82 Progestins Phase 3
83 Radiopharmaceuticals Phase 3
84 Estrogens Phase 3
85 Selective Estrogen Receptor Modulators Phase 3
86 Estrogen Receptor Modulators Phase 3
87 Hormone Antagonists Phase 3
88 Antineoplastic Agents, Hormonal Phase 3
89 Estrogen Receptor Antagonists Phase 3
90 Estrogen Antagonists Phase 3
91 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
92 Steroid Synthesis Inhibitors Phase 3
93 Aromatase Inhibitors Phase 3
94
Temoporfin Approved, Investigational Phase 2 122341-38-2
95
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
96
Simvastatin Approved Phase 2 79902-63-9 54454
97
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
98
Melphalan Approved Phase 2 148-82-3 460612 4053
99
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
100
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
101
chloroquine Approved, Investigational, Vet_approved Phase 1, Phase 2 54-05-7 2719
102
Naltrexone Approved, Investigational, Vet_approved Phase 2 16590-41-3 5360515
103
Ethanol Approved Phase 2 64-17-5 702
104
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
105
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
106
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
107
Enoxaparin Approved Phase 2 9005-49-6 772
108
Pancrelipase Approved, Investigational Phase 1, Phase 2 53608-75-6
109
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
110
Calcium carbonate Approved, Investigational Phase 2 471-34-1
111
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
112
Bevacizumab Approved, Investigational Phase 2 216974-75-3
113
Bazedoxifene Approved, Investigational Phase 2 198481-32-2
114
Talimogene laherparepvec Approved, Experimental, Investigational Phase 1, Phase 2 1187560-31-1
115
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
116
Racepinephrine Approved Phase 2 329-65-7 838
117
leucovorin Approved Phase 2 58-05-9 143 6006
118
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
119
Polyestradiol phosphate Approved Phase 2 28014-46-2
120
Palbociclib Approved, Investigational Phase 2 571190-30-2 5330286 11431660 5005498
121
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
122
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
123
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
124
Ramucirumab Approved, Investigational Phase 2 947687-13-0
125
nivolumab Approved Phase 1, Phase 2